Application bulletins
Reducing “time to market” is the ultimate goal for every pharmaceutical lab. Being the first on the market brings a competitive advantage for
prescription, over-the-counter, or generic-drug manufacturers. Applying quality-by-design
(QbD) principles at the formulation phase can
prevent tablet defects at an early stage and
thereby drastically reduce time during the
complex and troublesome phase of “scaleup.”
Waiting until late in development in the “production-size phase” may force scientists to
solve formulation issues at the pilot level or—even
worse—in actual production. A QbD approach,
however, secures the scale-up to production
with maximum safety right from the beginning.
Comments
No comments posted yet.
Add a comment
Articles you may like
Related products
Looking for additional information?
Let us help you